Journal Mobile Options
Table of Contents
Vol. 95, No. 3, 2003
Issue release date: November 2003
Nephron Clin Pract 2003;95:c77–c83

Compositional Lipoprotein Changes and Low-Density Lipoprotein Susceptibility to Oxidation in Chronic Renal Failure Patients with Heavy Proteinuria

Karabina S.A. · Pappas H. · Miltiadous G. · Bairaktari E. · Christides D. · Tselepis A. · Elisaf M. · Siamopoulos K.
Departments of aChemistry, Laboratory of Biochemistry, bNephrology and cInternal Medicine, and dLaboratory of Biological Chemistry, Medical School, University of Ioannina, Ioannina, Greece

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: There are limited data regarding qualitative lipoprotein abnormalities in undialysed uremic patients without proteinuria. In this report, we focused on lipoprotein changes observed in uremic patients with proteinuria as well as on the susceptibility of low-density lipoprotein (LDL) of these patients to oxidative modification in vitro. Methods: 20 patients with chronic renal failure [serum creatinine >1.6 mg/dl (141.4 µmol/l)], but not yet on renal replacement therapy, and with heavy proteinuria (>2 g/24 h), and 18 age- and sex-matched healthy individuals participated in the study. In both patients and controls, venous blood was collected for determination of serum lipid and lipoprotein levels, lipoprotein subfraction profile and chemical composition, as well as the susceptibility of LDL subfractions to oxidation. Results: Patients exhibited a more atherogenic lipid profile compared with the control population. Furthermore, the total very LDL + intermediate-density lipoprotein mass was increased in patients compared with controls, while this subfraction was triglyceride enriched in uremic patients. The total LDL concentration was significantly higher in patients compared with controls due mainly to an increase in the mass of all lipoprotein subfractions. It is noteworthy that the mass of small dense LDL was significantly elevated in patients compared with controls (135 ± 12 vs. 115 ± 11 mg/dl, p = 0.01), an increase which was more pronounced in hypertriglyceridemic patients. Furthermore, the subfraction high-density lipoprotein-2 mass was significantly lower in uremic patients compared with controls. Finally, no significant differences in the lag time, the rate of oxidation and the relative electrophoretic mobility values in each LDL subfraction between the two groups were observed. Conclusion: We conclude that uremic patients with heavy proteinuria exhibit compositional lipoprotein changes that are less marked than those observed in nonuremic patients with nephrotic syndrome. However, there is no evidence that circulating LDL isolated from these patients is more susceptible to oxidation in vitro than lipoprotein isolated from age- and gender-matched controls.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697–701.
  2. Raine AEG, McMahon SH, Selwood NH, Wing AJ, Brunner FP: Mortality from myocardial infarction in patients on renal replacement therapy. Nephrol Dial Transplant 1991;6:902–908.
  3. Foley RN, Parfrey PS, Sarnack MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:112–119.
  4. Attman P-O, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993;21:573–592.
  5. Elisaf M, Mikhailidis D, Siamopoulos KC: Dyslipidemia in patients with renal disease. J Drug Dev Clin Pract 1996;7:331–348.
  6. Elisaf MS, Bairaktari HT, Tsallas CS, Germanos NK, Siamopoulos KC: Atherogenic lipid and lipoprotein parameters in hemodialysis patients. Dial Transplant 1995;24:642–660.
  7. Warwick GL, Packard CJ: Lipoprotein metabolism in the nephrotic syndrome. Nephrol Dial Transplant 1993;8:385–396.
  8. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M: Abnormalities of lipoprotein metabolism in patients with nephrotic syndrome. N Engl J Med 1990;323:579–584.
  9. Jones JM, Shepherd J: Metabolism of apolipoprotein B-containing lipoprotein in subjects with nephrotic range proteinuria. Kidney Int 1991;40:129–138.
  10. O’Neal D, Lee P, Murphy B, Best J: Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996;27:84–91.
  11. Deighan CJ, Caslake MJ, McConnell M, Boulton Jones JM, Pachard CJ: Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000;35:852–862.
  12. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998;13:2281–2287.
  13. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones M, Packard CJ: Increased atherogenicity of low-density lipoprotein in heavy proteinuria. Nephrol Dial Transplant 1998;13:1183–1188.
  14. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: The atherogenic lipoprotein phenotype: Small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis 2001;157:211–220.
  15. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM: A density gradient ultracentrifugal procedure for isolation of the major lipoprotein classes from human serum. J Lipid Res 1981;22:339–358.
  16. Tselepis A, Doulias P-T, Lourida E, Glantzounis G, Tsimoyiannis E, Galaris D: Trimetazidine protects low-density lipoproteins from oxidation and cultured cells exposed to H2O2 from DNA damage. Free Rad Biol Med 2001;30:1357–1364.

    External Resources

  17. De Graaf J, Hak-Lammers HLM, Hectors MPC, Demacker PNM, Hendricks JCM, Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991;11:298–306.
  18. Elisaf MS, Petris C, Bairaktari E, Karabina S-A, Tzallas C, Tselepis A, Siamopoulos KC: The effect of moxonidine on plasma lipid profile and on LDL subclass distribution. J Hum Hypertens 1999;13:781–785.
  19. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339–349.
  20. Packard CJ, Shepherd J: Lipoprotein heretogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997;17:3542–3556.
  21. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882–888.
  22. Griffin BA, Freeman DJ, Tait GW, Thomson J, Caslake MJ, Packard CJ, Shepherd J: Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease. Atherosclerosis 1994;106:241–253.
  23. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875–881.
  24. Ambrosch A, Müller R, Freytag C, Borgmann S, Kraus J, Dierkes J, Neumann KH, König W: Small-sized low-density lipoproteins of subclass B from patients with end-stage renal disease effectively augment tumor necrosis factor-α-induced adhesive properties in human endothelial cells. Am J Kidney Dis 2002;39:972–984.
  25. Rubies-Prat J, Esinel E, Joven J, Ras R, Pira L: High-density lipoprotein cholesterol subfractions in chronic uremia. Am J Kidney Dis 1987;1:60–65.
  26. Eisenberg S: High-density lipoportein metabolism. J Lipid Res 1984;25:1017–1058.
  27. Westhuyzen J, Saltissi D, Healy H: Oxidation of low-density lipoprotein in hemodialysis patients: Effect of dialysis and comparison with matched controls. Atherosclerosis 1997;129:199–205.
  28. Loughrey CM, Young IS, McEneny J, et al: Oxidation of low-density lipoprotein in patients on regular haemodialysis. Atherosclerosis 1994;110:185–193.
  29. Sutherland WHF, Walker RJ, Ball MJ Stapley SA, Robertson MC: Oxidation of low-density lipoproteins from patients with renal failure of renal transplants. Kidney Int 1995;48:227–236.
  30. Maggi E, Bellazzi R, Falaschi F, et al: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 1994;45:876–883.
  31. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M: Oxidative stress markers in pre-uremic patients. Clin Nephrol 2001;56:308–314.
  32. Kleinveld HA, Naber AHJ, Stalenhoef AFH, DeMacher PNM: Oxidation resistance, oxidation rate and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: Studies in vitamin E deficient subjects. Free Radic Biol Med 1993;15:273–280.
  33. Reaven R, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL: Effects of oleate-rich and linoleate-rich diets on the susceptibility of low-density lipoproteins to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 1993;91:668–676.
  34. Abbey M, Belling GB, Noakes M, Hirata F, Nestel PJ: Oxidation of low-density lipoproteins: Intraindividual variability and the effect of dietary linoleate supplementation. Am J Clin Nutr 1993;57:391–398.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50